On Jun. 22, 2021, BioReference Laboratories, an OPKO Health company, announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers.

Unvaccinated guests were required to undergo rapid, point-of-care PCR COVID-19 prior to embarking. These guests also underwent rapid, COVID-19 point-of-care testing at the end of their voyage, before disembarking. Testing also took place on board, during the cruise.

BioReference Laboratories, is one of the largest full service specialty laboratories in the United States that gives healthcare providers and patients the power to make confident healthcare decisions. With a focus on genetics, oncology, urology and women’s health, BioReference offers comprehensive test solutions and unparalleled expertise based on a 40 year legacy of proven science. The company is in-network with the largest health plans in the United States, serves approximately 19 million patients annually, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 300 M.D., D.O., Ph.D., genetic counselors and other professional clinical and scientific personnel.